Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm

Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm Ren Homan, Ph.D., Co-Founder of Peptinovo Biopharma and Steve Tokarz, CEO of Peptinovo Biopharma   

Peptinovo Biopharma Selects Ardena as Manufacturing Partner to Advance Its Novel Cancer Nanotechnology Toward Clinical Trials

Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO) enabling precision medicines and other complex therapies. Ardena will manufacture Peptinovo’s cancer drug-delivery nanotechnology for the company’s planned launch of human clinical trials by year end.